海曲泊帕治疗恶性肿瘤化疗相关血小板减少的效果和安全性  

Hetrombopag’s Efficacy and Security in the Treatment of Thrombocytopenia by Chemotherapy

作　　者：庞丽娜[1] 龚帅[1] 张胜利[1] 张晓珂 王利叶 何炜[1] PANG Lina;GONG Shuai;ZHANG Shengli;ZHANG Xiaoke;WANG Liye;HE Wei(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,河南郑州450052

出　　处：《河南医学研究》2023年第22期4048-4051,共4页Henan Medical Research

摘　　要：目的 回顾性分析海曲泊帕治疗恶性肿瘤化疗引起血小板减少(CIT)的效果及安全性。方法 收集并分析2020年7月至2021年12月医院收治的恶性肿瘤化疗合并CIT≥2级患者的资料,筛选符合入组标准的患者100例。记录患者的性别、年龄、血小板计数(PLT)、药物剂量、是否序贯其他药物治疗、PLT<75×10^(9) L^(-1)的持续时间、血小板输注率、不良反应发生率等。结果 海曲泊帕治疗(16±3)d后,不同性别、年龄、美国东都肿瘤合作组(ECOG)评分、肿瘤类型、CIT分级及有无序贯治疗的CIT患者总有效率比较,差异无统计学意义(P>0.05),随着时间的延长,PLT回升至≥100×10^(9) L^(-1)占比、PLT较治疗前翻倍占比、PLT回升≥20×10^(9) L^(-1)占比及总有效率均逐渐升高,差异有统计学意义(P<0.001)。总不良反应发生率为2.0%,未发现血栓相关事件及CIT相关出血事件。100例患者CIT期间血小板输注共4人次。结论 海曲泊帕治疗恶性肿瘤化疗引起的血小板减少效果确切,且毒副反应小,患者耐受性良好。Objective To retrospectively analyze hetrombopag’s efficacy and security in the treatment of thrombocytopenia(CIT)by chemotherapy.Methods The data of malignant tumor chemotherapy combined with CIT≥2 patients admitted to the hospital from July 2020 to December 2021 were collected and analyzed,and 100 patients who met the inclusion criteria were screened.The patient’s gender,age,platelet count(PLT),medication dosage,whether other medication treatments are sequential,and duration of PLT<75×109 L-1,platelet transfusion rate,incidence of adverse reactions were recorded.Results There was no statistically significant difference in the total effective rate of CIT patients with different genders,ages,eastern cooperative oncology group(ECOG)scores,tumor types,CIT grades,and the presence or absence of sequential treatment after(16±3)days of treatment with Hetrombopag(P>0.05).As time goes on,PLT rebounds to≥100×10^(9) L^(-1) proportion,PLT doubling proportion compared to before treatment,PLT recovery≥20×10^(9) L^(-1) proportion and total effective rate of gradually increased,and the difference was statistically significant(P<0.001).The total incidence of adverse reactions was 2%,and no thrombosis related events or CIT related bleeding events were found.A total of 4 platelet transfusions were performed during CIT in 100 patients.Conclusion Hetrombopag has a definite therapeutic effect on thrombocytopenia caused by chemotherapy in malignant tumors,with minimal toxic side effects and good patient tolerance.

关 键 词：海曲泊帕 化疗引起血小板减少 化疗 恶性肿瘤 血小板 

分 类 号：R730.6[医药卫生—肿瘤]